Article about canalevia-ca1, jaguar health's prescription drug conditionally approved by the fda for the treatment of chemotherapy-induced diarrhea in dogs, published in petvet magazine

Canalevia®-ca1 is a canine-specific formulation of crofelemer, jaguar's novel, oral plant-based drug sustainably harvested from the croton lechleri tree crofelemer, the active ingredient in canalevia ca-1, is the subject of jaguar's recently conducted phase 3 ontarget trial in humans for cancer therapy-related diarrhea san francisco, ca / accesswire / december 5, 2024 / jaguar health, inc. (nasdaq:jagx) (jaguar) today announced that an article about canalevia-ca1 (crofelemer delayed-release tablets), jaguar's prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs, has been published in petvet magazine and can be viewed by clicking here. canalevia-ca1 is conditionally approved by the u.s. food and drug administration for the treatment of cid in dogs and is the first and only treatment for cid in dogs to receive any approval from the fda.
JAGX Ratings Summary
JAGX Quant Ranking